Chronocort
Sponsors
Neurocrine UK Limited
Conditions
21-Hydroxylase DeficiencyAdrenal InsufficiencyAdrenogenital SyndromeCongenital Adrenal HyperplasiaPrimary Adrenal Insufficiency
Phase 1
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
CompletedNCT00519818
Start: 2007-08-31End: 2009-05-31Updated: 2022-04-26
An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone
CompletedNCT03019614
Start: 2010-03-31End: 2010-04-30Updated: 2017-01-12
A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort Formulations
CompletedNCT03051893
Start: 2011-02-28End: 2012-04-30Updated: 2017-02-14
Phase 2
Phase 3
Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
CompletedNCT05063994
Start: 2022-05-24End: 2024-02-02Updated: 2025-02-25
Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia
CompletedNCT05299554
Start: 2022-04-01End: 2026-01-15Updated: 2026-02-04